Comparative efficacy and safety of PD-1/PD-L1 inhibitors versus docetaxel in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.

J Thorac Dis · 2025 · PMC12603480 · PMID 41229814

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Therefore, while the current findings support a favorable trend for PD-1/PD-L1 inhibitors over docetaxel, the presence of bias may attenuate the strength of the evidence, particularly with respect to the magnitude of OS benefit.

also in 1,053 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.